How Growth Hormone Affects IGF-1

Growth hormone stimulates IGF-1 (insulin-like growth factor 1) production primarily through the liver via the JAK2-STAT5 signalling pathway:

1. Hepatic production: Approximately 75% of circulating IGF-1 is produced by the liver in direct response to GH receptor activation. GH binds its receptor on hepatocytes, activating JAK2 kinase, which phosphorylates STAT5b transcription factors. STAT5b translocates to the nucleus and drives IGF-1 gene expression.
2. Dose-response relationship: The IGF-1 response is tightly correlated with GH dose. Each incremental increase in GH produces a proportional rise in IGF-1, though the relationship plateaus at very high doses as hepatic production capacity saturates.
3. Binding proteins: Over 95% of circulating IGF-1 is bound to IGF-binding proteins (IGFBPs), primarily IGFBP-3 and acid-labile subunit (ALS). GH also stimulates IGFBP-3 production, extending IGF-1's circulating half-life from minutes (free) to 12-16 hours (bound).
4. Autocrine/paracrine effects: GH also stimulates local IGF-1 production in muscle, bone, and cartilage. These local effects contribute to GH's anabolic actions but are not reflected in serum IGF-1 measurements.

The net result is that exogenous GH produces sustained supraphysiological IGF-1 levels, which mediate the majority of GH's anabolic, lipolytic, and proliferative effects.

Low-dose (1-3 IU/day):

• IGF-1 typically rises to 150-350 ng/mL
• Usually within the upper normal range for young adults (age-dependent)
• Mild anabolic and recovery effects, generally considered the "health and longevity" dose range

Moderate doses (4-6 IU/day):

• IGF-1 commonly rises to 350-600 ng/mL
• Exceeds the upper limit of normal for most age groups
• Noticeable improvements in body composition, recovery, and connective tissue repair

High doses (8-15+ IU/day):

• IGF-1 can reach 600-1000+ ng/mL
• Significantly supraphysiological; well above any natural reference range
• Strong anabolic effects but accelerated risk profile (organ growth, insulin resistance, potential tumour promotion)

Timing: IGF-1 peaks 3-6 hours after subcutaneous GH injection and remains elevated for 12-20 hours due to IGFBP-3 binding. Steady-state IGF-1 levels are reached after 1-2 weeks of consistent daily dosing.

Age matters: Natural IGF-1 peaks around age 15-20 (often 300-400+ ng/mL) and declines roughly 14% per decade thereafter. A 40-year-old with an IGF-1 of 350 ng/mL is already above their age-adjusted range even though it would be normal for a 20-year-old.

Baseline: Obtain IGF-1 before starting GH. Note your age-adjusted reference range from the lab report. Labs use different assays, so always compare results from the same laboratory.

During use:

• IGF-1: at 4 weeks (initial dose response), then every 3 months
• Always draw blood at a consistent time relative to your GH injection (ideally 12-18 hours post-injection for trough-level monitoring, or 3-6 hours post for peak assessment)
• Document which assay and lab you use, as IGF-1 reference ranges vary significantly between assays (LC-MS/MS vs immunoassay)

Key benchmarks:

• Under 1.5x upper limit of normal (ULN) for your age: generally acceptable risk profile
• 1.5-3x ULN: moderate risk, warrants dose reassessment
• Above 3x ULN: high risk for adverse effects, dose reduction strongly recommended

Complementary markers:

• IGFBP-3: rises in parallel with IGF-1; useful for confirming GH bioactivity
• Fasting glucose and insulin: monitor concurrently for metabolic effects
• Free T3: GH accelerates T4-to-T3 conversion

Dose titration strategy:

• Start low (1-2 IU/day) and check IGF-1 at 4 weeks
• Increase by 1 IU increments with repeat IGF-1 testing 3-4 weeks after each adjustment
• Target the minimum dose that achieves your desired IGF-1 level within an acceptable risk range

Safety thresholds:

• Conservative approach: keep IGF-1 below 1.5x ULN for your age
• Moderate approach: up to 2x ULN with regular monitoring
• Avoid sustained levels above 3x ULN; the risk of acromegalic features (jaw growth, hand/foot enlargement, organ enlargement) and potential cancer promotion rises substantially

If IGF-1 is excessively elevated:

• Reduce GH dose by 25-50% and recheck in 3-4 weeks
• Splitting the daily dose (AM + PM) may produce lower peak IGF-1 vs a single bolus
• Every-other-day dosing protocols produce lower average IGF-1 but sacrifice some anabolic consistency

Long-term considerations:

• Sustained supraphysiological IGF-1 is associated with increased colorectal cancer risk in epidemiological studies
• Cardiac hypertrophy risk increases with chronic IGF-1 elevation
• Acromegalic changes (soft tissue growth, joint pain) are cumulative and may become irreversible
• Periodic "GH holidays" (4-8 weeks off per year) allow IGF-1 to normalise and may reduce long-term risks